Member Info for Saxondale

Looking ahead - the huge costs of developing a drug , can give the company some huge tax savings once the drug hits the market - see below details . Puts into perspective the amount that has been spent so far getting Bex to where it is .

Not only still 100% wholly owned , but can offset the losses against tax for the next 10 years of profits .

47 million euros of cumulative tax losses so far
91.8 million euros of R&D expenditure in the last 10 years .

The costs really are staggering when you add them up - but hence these massive price tags when companies or therapies are sold .

The Company’s tax credit for the fiscal year 2022 can
be recorded only after the Finnish tax authorities have
approved the tax report and confirmed the amount of
tax-deductible expenses. The total amount of cumulative
tax losses carried forward approved by tax authorities on
December 31, 2022 was EUR 47.1 million (2021: EUR 41.0
million). The Company estimates that it can utilize most
of these during the years 2023 to 2033 by offsetting them
against future profits.
In addition, the Company has EUR 91.8 million of R&D
costs incurred in the financial years 2010 - 2022 that have
not yet been deducted from taxation. This amount can
be deducted over an indefinite period at the Company’s
discretion

The request to have that amount of shares available to deploy( 20%) is pretty standard these days . It means they have permission , should the need arise , or suit their plan . It doesn't mean that they will , it just saves an EGM should they need to .

I think 2023 is going to be THE year for Faron .

Why ?

I notice they have requested to add a new board member - Tuomo Patsi .

Not sure what he is doing exactly now , but I can see he was appointed president of Celgene ( for Europe etc) in 2014 . Celgene got bought out by Bristol Myers Squibb in 2019 for $74 billion .

So they have recruited a top bod in the cancer pharma world , just for a year ( until next AGM) . I wonder why ?

The Board proposes, on the basis of the proposal of the nomination committee, that Tuomo Pätsi be elected as a new member to the Board for a term that ends at the end of the next AGM.
Tuomo Pätsi, citizen of Finland and Switzerland, holds no other board memberships at the moment. He is
independent of the Company and its significant shareholders.

https://bloodcancerstoday.com/post/bexmarilimab-has-therapeutic-potential-for-myeloid-malignancies

Not too sure . I know other companies I have followed have had dates there ( a decision date for approval/non approval ).
I'd say that Faron would inform us if a such a decision meeting date had been assigned .
Not much else to go on at the moment . The Clinical.gov site listings have hardly changed for a while now . Bexmab last update was July 2022 , although we know they have new study sites in US .
Hopefully an update soon .

Many thanks Sophie .

Yes , I think everyone now expects some kind of partnership deal to fund the future of Bex .
Markku and family , being large shareholders , also would not wish to continually dilute the share holding just to creep forward a few months at a time .
The Matins package , along with Bexmab P1 data , should now be enough to satisfy any interested party .

Now is the right time .

Just translating the headlines -
Faron is a risk tag for investors, whose price is based on the potential of one drug prototype in particular - "If the initial flow of good information continues, it could be a value driver for the share this year"

There is a market and demand for the medicine developed by Faron, if it proves to be effective and safe in studies. A lot of money will come back along the way

The share price of drug developer Faron Pharmaceuticals has seen plenty of strong movements since the company, already listed in London, also entered the First North list of the Helsinki Stock Exchange in 2019.

Drug development consumes a lot of money and Faron's cash is enough for May - "Sooner or later the company needs a partnership deal"

Drug research consumes a lot of capital. For companies that are still in the early stages of commercialization, it probably also means hitting the owners' pockets.

For example, Faron Pharmaceuticals, which is listed on the First Nort of the Helsinki Stock Exchange, raised 12 million euros with its share issue in January. The amount was bigger than, for example, in a few IPOs seen last year.

And not forgetting they are always ahead of what we know .
They filed for the 'Haematokine' trademark in 2021 too in the US , and it was registred in Aug 2022 .
https://tmsearch.uspto.gov/bin/showfield?f=doc&state=4804:ipgq39.2.1

Haven't read it in detail , but I'm assuming this is Heamatokine related - so expanding H's potential .
Haematokine is Faron’s investigational A0C3 inhibitor targeting VAP-1, a target discovered by Faron’s scientific founders. Hematopoietic Stem Cell Transplantation (HSCT) is standard of care in many hematological malignancies. Transplant failure is a lethal complication and is a result of poor expansion of transplanted cells, which can occur in over 25% of patients. Haematokine is the expansion of hematopoietic stem cells by regulating AOC3 activity for the use in regenerative medicine and hematological malignancies. This program, currently in pre-clinical development, has the potential to benefit all indications where an expansion of haemopoietic stem cells is needed. Haematokine is undergoing IND-enabling studies.

This just landed -
https://patents.justia.com/patent/20230046617
The findings of the present invention provide a method for expanding HSCs in clinical applications using VAP-1 inhibitors. The findings of the present invention may help to improve bone marrow recovery after injury, enhance the effects of bone marrow transplantation and ameliorate the mobilization, harvesting and expansion of HSCs. Further, the findings of the present invention provide a novel method for treating several hematological diseases or conditions, which benefit from expanded population of hematopoietic stem cells. The present invention provides a method for treating a condition in which bone marrow does not function normally and the patient is in need of boosting his/her hematopoiesis. In one aspect, the findings of the present invention provide a novel efficient method for increasing ex vivo the number of umbilical cord blood HSCs, since umbilical cord blood transplantation (UCBT) has become an established therapy for patients without matched donors, leading to cures of previously incurable disease.

Yep , somebody was eager to add a bit today , and it doesn't take much of that kind of activity to move the needle on this share .
MLF said that they are looking forward to providing more positive patient data . With Bexmab , its a 28 day cycle , so every month they get a new batch of data for each patient , and the whole cohort timescale is about 4 months .
They obviously have recent data that we don't know about yet , and she is very positive .
A good sign .

Yep , very positive .
She said 2 of the 3 responders had been on the drug before , so the response with Bex was almost clinical proof .
I remember hearing 1 had been , but not 2 .
That makes these results even more outstanding .
Bristol Myers Squibb will be watching this closely , and no doubt have Farons number on speed dial ( if that's even a thing anymore lol )

Good to see them planning to be at so many events , they obviously expect to busy spreading their good data .

Lots of activity just been posted up on the Faron website - 6 events/meetings/conferences in the next 4 months .
https://www.faron.com/investors/calendar

Oncology / Hematology meetings , plus firstly an Investor event in mid March .

Steady and sensible - build up the company now .

The Company anticipates converting 9 research sites to FDA approved configuration and clinical use, selling 75 to 100 Xenoview Gas Blend cylinders and 15 to 20 Polarizer systems over the next 24 months.
The Company will focus Business Development activities with respiratory drug and radiology contrast agent manufacturers, pulmonary drug clinical trial CROs, and MRI system manufacturers to monetize their use of our technology to leverage their commercial activities.

https://twitter.com/FaronPharm/status/1623637096433958913?s=20&t=lNy-AKP6s1gcCImO6Gf1nA

Looks like a team building weekend .
Makes you appreciate how many people are working behind the scenes on Bex , and getting this progressed .

They look a happy bunch to be honest , and you can imagine the morale is pretty high at the moment .

Late 2019 for me , but started adding big time March 2020 .
Always remember buying a pile at about 2.5p during the slump , then literally a minute later a GH director buy RNS landed.
And that was the start of the epic rise .
Did take a good chunk off at 24p , then started adding again at 14p , and now hold more shares than I've ever had .
Bought a big wedge last week before the Newmont news . Wasn't expecting a nice rise , just felt I needed more shares as I was still averaging down.
Plus this is just a share that just draws you back in .
Average is now 8p exactly , so now sitting back and looking forward to developments .

Did get a chunk at 14.9 after some effort about 30 mins ago . Happy enough with that .

correction - he owns 12.5m shares , not 20m .

so he's bought 10 million shares since April 2019 at the going rate pretty much .

Timo owned about 7% back in April 2019 , which was about 2.5 million shares ( only 35 million in total)

He now owns 20% , which is about 20 million shares ( from a total of 63 million )

So he's added 17.5 million shares since that low point in 2019 when the SP was 65p , but since then the placings have been from £1 through to £2.80 odd , and he's added all through that period .

The bulk of his purchases have been in the last few years , and although I expect he probably swept up a good chunk under a quid , he's also had to pay a lot more for much of them too , particularly recently .

So he probably has an average similar to many LTH's , perhaps £1.80 or perhaps a bit more . I don't know really its just a guess. It may be higher as many were adding in the £7-8 zone in 2018 .

Either way - I don't see him starting to dump shares if we get to £5 or £7 through some breakthrough news .

The commitment he's shown , like many of us in our own ways , leads me to think that he will be here right until the ultimate goal is achieved .

I guess it depends on what its approved for .
Approval for AML would give us a lift off , but its the further approvals where bigger money would come .
What one license would do is fund the rest of the trials .
Similar in some respects to Avacata , where they have multiple uses lined up , just need one approval and they are self sufficient and able to prove up the next ones in the pipeline .

In that situation , unless the company gets bought out , the SP should rerate and then build as further progress is made .

Liam , I echo Saints7 comments . Really appreciate all your efforts . This last interview may really go down as a classic . I enjoy all your youtube vids . Long may they continue as this new chapter of GGP begins .